Inovio制药 INO 深 沪
已收盘 03-27 16:00:00 美东时间
1.61
+0.060
+3.87%
华盛通- 最 高1.62
- 今 开1.54
- 成交量 149.14万股
- 最 低 1.50
- 昨 收 1.55
- 总市值 1.11亿
- 52周最高 2.9789
- 市盈率 静 --
- 换手率 2.17%
- 52周最低 1.30
- 委 比 -47.85%
- 总股本 6870.34万
- 历史最高 405.48
- 量 比 2.06
- 振 幅 7.74%
- 历史最低 1.30
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多电话会总结 ｜ Inovio(INO)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Inovio业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至2025年第四季度末，公司持有现金、现金等价物和短期投资5,850万美元，较2024年12月31日的9,410万美元大幅下降。 **净利润/亏损：** - 2025年第四季度实现净利润380万美元（每股0.06美元） - 2025年全年净亏损8,490万美元（每股1.81美元） **运营费用：** - 2025年第四季度运营费用1,750万美元 - 2025年全年运营费用8,690万美元 ## 2. 财务指标变化 **现金流变化：** 现金及等价物
03-18 12:26
Pomerantz files securities class action against Inovio Pharmaceuticals in Pennsylvania federal court
Pomerantz files securities class action against Inovio Pharmaceuticals in Pennsylvania federal court Pomerantz LLP said a securities class action was filed against Inovio and certain officers in the U.S. District Court for the Eastern District of Pennsylvania (26-cv-00803). The suit covers investors
03-12 22:00
Major earnings expected after the bell on Thursday include:
Major earnings expected after the bell on Thursday include: Adobe (ADBE) Wheaton Precious Metals Corp. (WPM) SentinelOne (S) Inovio Pharmaceuticals (INO) Ulta Beauty (ULTA) Other Earnings slated for r...
03-12 22:00
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Inovio Faces Securities Class Action Lawsuit Over FDA Review Timeline Disclosure
Inovio Faces Securities Class Action Lawsuit Over FDA Review Timeline Disclosure Levi & Korsinsky has reminded investors of a pending securities class action against Inovio Pharmaceuticals seeking damages for purchasers of the company’s securities between Oct. 10, 2023 and Dec. 26, 2025. The complai
03-04 22:02
Akeso, INOVIO Collaborate To For Evaluation Of Akeso's Cadonilimab PD-1/CTLA-4 Bispecific AntibodyIn Combination With INO-5412 To Treat Glioblastoma
Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab,
03-04 21:55
BRIEF-Akeso And Inovio Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)
BRIEF-Akeso And Inovio Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm) March 4 (Reuters) - Akeso Inc 9926.HK : AKESO AND INOVIO ANNOUNCE CLINICAL COLLABORATION TO ADVANCE NOVEL COMBINATION THERAPY FOR GLIOBLASTOMA (GBM) Source text: ID:nPn6x2Nfja Further c
03-04 21:53
Akeso, INOVIO team up to test cadonilimab plus INO-5412 in GBM trial
Akeso, INOVIO team up to test cadonilimab plus INO-5412 in GBM trial Akeso Inc. and INOVIO have entered into a clinical trial collaboration and supply agreement to evaluate Akeso’s cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with INOVIO’s DNA immunotherapy candidate INO-5412 for t
03-04 21:53
BRIEF-Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)
BRIEF-Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm) March 4 (Reuters) - Akeso Inc 9926.HK : INOVIO AND AKESO ANNOUNCE CLINICAL COLLABORATION TO ADVANCE NOVEL COMBINATION THERAPY FOR GLIOBLASTOMA (GBM) INOVIO - DOSING IN COMBINATION THERA
03-04 21:06
Inovio’s INO-3107 Timeline Under Scrutiny After Accelerated Approval Setback
Inovio Pharmaceuticals ($INO) investors experienced sharp volatility following ...
03-04 17:41
